Vor Bio, a clinical-stage cell and genome engineering company, has appointed Mr. Erez Kalir to its Board of Directors, creating a new seat following a recent private investment in public equity ...

Dec. 27, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it has entered into a securities purchase agreement for a private ...

Vor Biopharma has entered into a Securities Purchase Agreement for a $55.6 million private placement to issue shares and warrants, with the proceeds intended to fund clinical and preclinical ...

Vor Bio (NASDAQ:VOR) shares soared more than 20% in Friday pre-market trading, after it said that it has entered into a securities purchase agreement for a private investment in public equity ...

Vor announced it entered into a securities purchase agreement for a private investment in public equity financing. The company expects to generate about $55.6 million in gross proceeds. Vor ...

CAMBRIDGE, Mass., Dec. 27, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it has entered into a securities purchase ...